✦ LIBER ✦

Radioresistant and repair proficient tumor cells may be associated with local failure in head and neck cancer

✍ Scribed by R.R. Weichselbaum; W. Dahlberg; M. Beckett; T.J.U Ervin

Publisher: Elsevier Science
Year: 1986
Tongue: English
Weight: 134 KB
Volume: 12
Category: Article
ISSN: 0360-3016
DOI: 10.1016/0360-3016(86)90639-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Protein signatures associated with tumor

Protein signatures associated with tumor cell dissemination in head and neck cancer

✍ Onno B. Bleijerveld; Ruud H. Brakenhoff; Tieneke B.M. Schaaij-Visser; J. Mirjam 📂 Article 📅 2011 🏛 Elsevier 🌐 English ⚖ 871 KB

Head and neck squamous cell carcinoma (HNSCC) is the sixth most common type of cancer worldwide. Strong prognostic indicators that predict development of distant metastases are the presence and number of lymph node metastases in the neck, and extranodal spread. Recently, it was shown in several stu

Association of CD44 V3-containing isofor

Association of CD44 V3-containing isoforms with tumor cell growth, migration, matrix metalloproteinase expression, and lymph node metastasis in head and neck cancer

✍ Steven J. Wang; Volkert B. Wreesmann; Lilly Y. W. Bourguignon 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 385 KB 👁 2 views

## Abstract ## Background. The CD44 family of receptors includes multiple variant isoforms, some of which have been linked to tumor progression. The objective of this study was to investigate whether CD44 v3‐containing isoforms are involved in head and neck squamous cell carcinoma (HNSCC) tumor pr

Acquired cisplatin resistance in the hea

Acquired cisplatin resistance in the head–neck cancer cell line Cal27 is associated with decreased DKK1 expression and can partially be reversed by overexpression of DKK1

✍ Eva M. Gosepath; Niels Eckstein; Alexandra Hamacher; Kati Servan; Georg von Jonq 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 French ⚖ 301 KB 👁 1 views

## Abstract Head and neck cancers are treated by a combination of surgery, radiotherapy and/or chemotherapy. The clinical success of cisplatin‐based chemotherapy, mostly in combination with 5‐FU or a taxane, is however limited by multifactorial intrinsic or acquired resistance. So far, known genes